US equities |
MU $1,054.71 ▼-3.06% NVDA $233.46 ▼-1.69% SNDK $1,617.48 ▼-4.43% AMD $625.85 ▼-3.10% PLTR $197.40 ▲+1.69% INTC $108.09 ▼-4.45% SPCX $161.95 ▼-3.37% META $714.72 ▼-0.91%
FinancialContent

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

45.76 +0.11 (+0.24%)
Delayed Quote Updated: 12:50 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock ↗
 
Via Benzinga
News headline image
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 6 Analyst Projections For AnaptysBio ↗
 
Via Benzinga
News headline image
Where AnaptysBio Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Expectations For AnaptysBio's Future ↗
 
Via Benzinga
News headline image
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
Crude Oil Gains 1%; US Composite PMI Surges In March ↗
 
Via Benzinga
News headline image
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Anaptys Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in March Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment ↗
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment. 
Via Investor's Business Daily
News headline image
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data ↗
AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming trial results in 2025-2026. 
Via Benzinga
News headline image
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
From AnaptysBio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >